Tranquis Therapeutics Granted FDA Orphan Drug Designation for TQS-168 for the Treatment of Amyotrophic Lateral Sclerosis – Yahoo Finance

Tranquis Therapeutics Granted FDA Orphan Drug Designation for TQS-168 for the Treatment of Amyotrophic Lateral Sclerosis – Yahoo Finance
Tranquis Therapeutics Granted FDA Orphan Drug Designation for TQS-168 for the Treatment of Amyotrophic Lateral Sclerosis  Yahoo Finance ... read more
Source: Google NewsPublished on 2022-06-21

Related Articles:

  • Hope fatigue: will there ever be a cure? February 1, 2020 Saturday 1 February 2020At the start of 2020 there was a flurry of posts on various Parkinson’s forums about all the promising research and clinical trials in progress, not to mention a few puns around “20/20 vision”.Rather than repeat it all here (and probably get some of it wrong), I would refer you instead to The Science of Parkinson’s take…
  • The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
  • The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
  • Prevail lands on a Lilly pad December 15, 2020 # # # # 2020 has been a dreadful year for most of the world – burdened by the outbreak and consequences of COVID-19. Despite this, there has been a steady stream of biotech acquisitions related to Parkinson’s which have helped to keep morale high in the PD research community. In October alone, we saw the Portuguese pharmaceutical company Bial…
  • The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
  • Tranquis Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of TQS-168 - Business Wire June 2, 2022 Tranquis Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of TQS-168  Business Wire
  • Tranquis Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of TQS-168 - Yahoo Finance June 2, 2022 Tranquis Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of TQS-168  Yahoo Finance
  • Monthly Research Review – July 2021 July 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during July 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
  • Monthly Research Review – January 2021 January 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during the previous 4 weeks. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical…
  • FDA Grants Regenerative Medicine Advanced Therapy Designation to VY-AADC for Parkinson’s June 25, 2018 The U.S. Food and Drug Administration granted Voyager Therapeutics’ gene therapy candidate VY-AADC regenerative medicine advanced therapy (RMAT) designation for the treatment of therapy-resistant motor fluctuations in Parkinson’s patients. The RMAT designation, recently created by the FDA, is given to regenerative medicine products intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition, and that have early…
  • Neuropore Receives Orphan Drug Designation for NPT520-34 for the Treatment of Amyotrophic Lateral Sclerosis - Yahoo Finance August 14, 2019 Neuropore Receives Orphan Drug Designation for NPT520-34 for the Treatment of Amyotrophic Lateral Sclerosis  Yahoo FinanceNeuropore Therapies, Inc. announced today that it has received orphan drug designation for NPT520-34 for the treatment of amyotrophic lateral sclerosis or ALS ...
  • Novel Treatment for ALS Gains Orphan Drug Status August 19, 2019 The Food and Drug Administration (FDA) has granted Orphan Drug designation to an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).  NPT520-34 (Neuropore Therapies) is an orally bioavailable, blood-brain barrier penetrating small molecule which has been shown to reduce markers of brain neuroinflammation by decreasing neurotoxic misfolded proteins (superoxide dismutase 1) in animal models. Related ArticlesSignificant Motor Cortex…
  • Monthly Research Review: January 2022 January 31, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2022. The post is divided into 10 parts based on the type of research: Top 6 pieces of Parkinson’s news Articles of general interest Basic biology…
  • Monthly Research Review – October 2021 October 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during October 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
  • Neuropore Receives Orphan Drug Designation for NPT520-34 for the Treatment of Amyotrophic Lateral Sclerosis - Business Wire August 14, 2019 Neuropore Receives Orphan Drug Designation for NPT520-34 for the Treatment of Amyotrophic Lateral Sclerosis  Business WireNPT520-34 receives orphan drug designation from the FDA's Office of Orphan Product Development for treatment of ALS.
  • APB-102 Receives Orphan Drug Designation for Genetic SOD1 ALS July 25, 2019 The Food and Drug Administration (FDA) has granted Orphan Drug designation to APB-102 (Apic Bio, Inc.) for the treatment of genetic superoxide dismutase 1 (SOD1) enzyme amyotrophic lateral sclerosis (ALS). SOD1 ALS is caused by mutations in the gene that produces the copper zinc SOD1 enzyme, which leads to the degeneration of motor neurons and muscle control typically seen in…
  • PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome - Yahoo Finance October 13, 2021 PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome  Yahoo Finance
  • Prevail’s Gene Therapy Candidate PR001 Granted FDA Fast Track Status July 10, 2019 The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Prevail Therapeutics’ lead gene therapy candidate, PR001, for the treatment of people with Parkinson’s disease associated with GBA1 gene mutations. Fast Track status will support and expedite the clinical development, regulatory review, and potential marketing approval of PR001. The FDA’s decision follows its acceptance of Prevail’s Investigational New…
  • FDA Names Spectramax Light Therapy ‘Breakthrough Device’ for Parkinson’s May 4, 2020 The United States Food and Drug Administration (FDA) has granted breakthrough device designation to PhotoPharmics‘s light-based, at-home device as an add-on therapy for Parkinson’s disease. This designation is given to medical devices with the potential to offer more effective treatment for life-threatening or debilitating diseases. It grants the company access to experts at the FDA during development, and paves the way…
  • FDA Grants Breakthrough Device Designation for nQ Medical’s neuroQWERTY February 11, 2020 The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to nQ Medical’s neuroQUERTY software, which is designed to monitor brain health and Parkinson’s disease progression. Breakthrough device status is given to medical devices that have the potential to be an effective treatment or diagnostic tool for life-threatening or irreversibly debilitating diseases. The status speeds the review and assessment…
  • The Bluerockers have started July 15, 2021 # # # # On the 8th June, BlueRock Therapeutics put out a press release announcing that the first participant in their Phase I clinical trial of cell transplantation for Parkinson’s had been dosed (Click here to read the press release). The initiation of this clinical trial by the company is a major step forward for them and for the…
  • Getting expansive about treg cells August 5, 2021 # # # # In cancer research, scientists have devised methods of extracting samples of blood from patients and then growing certain populations of cells in those samples. The isolated subpopulations  of cells can then be manipulated in cell culture, before they are then injected back into the patient. This is a form of immunotherapy – artificially boosting the immune system…